Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
10-hydroxycamptothecin + Arsenic trioxide
|
DCALZTR
|
10-hydroxycamptothecin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ABIRATERONE + Arsenic trioxide
|
DCBSAM3
|
ABIRATERONE
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
ABIRATERONE + Arsenic trioxide
|
DCEW4WX
|
ABIRATERONE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Aminolevulinic Acid Hydrochloride + Arsenic trioxide
|
DC3RF34
|
Aminolevulinic Acid Hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Aminolevulinic Acid Hydrochloride + Arsenic trioxide
|
DC2M1J9
|
Aminolevulinic Acid Hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Aminolevulinic Acid Hydrochloride + Arsenic trioxide
|
DCQLAMF
|
Aminolevulinic Acid Hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Aminolevulinic Acid Hydrochloride + Arsenic trioxide
|
DC7OB8J
|
Aminolevulinic Acid Hydrochloride
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Aminolevulinic Acid Hydrochloride + Arsenic trioxide
|
DC90TGY
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Anastrozole + Arsenic trioxide
|
DCQCPHO
|
Anastrozole
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Arfolitixorin + Arsenic trioxide
|
DCO5NPC
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Azacitidine + Arsenic trioxide
|
DC7F475
|
Azacitidine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Bendamustine hydrochloride + Arsenic trioxide
|
DCME8PC
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bendamustine hydrochloride + Arsenic trioxide
|
DCSMLF8
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Bleomycin + Arsenic trioxide
|
DC4BJG1
|
Bleomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Bleomycin + Arsenic trioxide
|
DCM5E68
|
Bleomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Bleomycin + Arsenic trioxide
|
DCP9OFD
|
Bleomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Bleomycin + Arsenic trioxide
|
DC1PTL3
|
Bleomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Bleomycin + Arsenic trioxide
|
DCPUV1O
|
Bleomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Bleomycin + Arsenic trioxide
|
DCMG8AP
|
Bleomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Bleomycin + Arsenic trioxide
|
DCWVJNA
|
Bleomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Bortezomib + Arsenic trioxide
|
DCOJ7RH
|
Bortezomib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DC5H25W
|
Bortezomib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCTEXTR
|
Bortezomib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCFRGCQ
|
Bortezomib
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DC6DEBR
|
Bortezomib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCCSUTB
|
Bortezomib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCWQ15M
|
Bortezomib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCKBIU2
|
Bortezomib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCA36C5
|
Bortezomib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCGHFRL
|
Bortezomib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCNQWXX
|
Bortezomib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCDJ6SM
|
Bortezomib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Bortezomib + Arsenic trioxide
|
DCFRY7M
|
Bortezomib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Busulfan + Arsenic trioxide
|
DCLLOT2
|
Busulfan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Busulfan + Arsenic trioxide
|
DC03LMF
|
Busulfan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Busulfan + Arsenic trioxide
|
DCOMBER
|
Busulfan
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Busulfan + Arsenic trioxide
|
DCITNW0
|
Busulfan
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Chlorambucil + Arsenic trioxide
|
DCL15NA
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Chlorambucil + Arsenic trioxide
|
DCZ2MNU
|
Chlorambucil
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Chlorambucil + Arsenic trioxide
|
DC0H93M
|
Chlorambucil
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Chlorambucil + Arsenic trioxide
|
DCXY8AG
|
Chlorambucil
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCML61U
|
Cisplatin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCKFP9B
|
Cisplatin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DC99Z6C
|
Cisplatin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCSF15H
|
Cisplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCOX0WL
|
Cisplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCSPGI8
|
Cisplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCZ3R2L
|
Cisplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCWEUKQ
|
Cisplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCPE2HU
|
Cisplatin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCL94B3
|
Cisplatin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCFBUUW
|
Cisplatin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCGN0H8
|
Cisplatin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCO0QPY
|
Cisplatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DCLUHQW
|
Cisplatin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Cisplatin + Arsenic trioxide
|
DC4MFLB
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Cisplatin + Arsenic trioxide
|
DCJ748Z
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Crizotinib + Arsenic trioxide
|
DCZ33RS
|
Crizotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Crizotinib + Arsenic trioxide
|
DC5Z19F
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Dacarbazine + Arsenic trioxide
|
DC9C5W1
|
Dacarbazine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Dactinomycin + Arsenic trioxide
|
DCVZZRL
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Dactinomycin + Arsenic trioxide
|
DCTXSGS
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Dactinomycin + Arsenic trioxide
|
DCXIH6B
|
Dactinomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[3] |
|
Dactinomycin + Arsenic trioxide
|
DCGK5NJ
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Dactinomycin + Arsenic trioxide
|
DCRZCI3
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Dactinomycin + Arsenic trioxide
|
DC960VG
|
Dactinomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Dactinomycin + Arsenic trioxide
|
DC8U2HY
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Dasatinib + Arsenic trioxide
|
DCOJC57
|
Dasatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Dasatinib + Arsenic trioxide
|
DC32A0S
|
Dasatinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Dasatinib + Arsenic trioxide
|
DCI4O6B
|
Dasatinib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Dexrazoxane + Arsenic trioxide
|
DC75L66
|
Dexrazoxane
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Dexrazoxane + Arsenic trioxide
|
DCWZY16
|
Dexrazoxane
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Digitoxin + Arsenic trioxide
|
DC9OU63
|
Digitoxin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Digitoxin + Arsenic trioxide
|
DC039Q7
|
Digitoxin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Digitoxin + Arsenic trioxide
|
DCUKX5B
|
Digitoxin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Digitoxin + Arsenic trioxide
|
DCEN60M
|
Digitoxin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCD1VX8
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCPNUZC
|
Docetaxel
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCDC4MH
|
Docetaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DC9GRZH
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DC297E4
|
Docetaxel
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCDNY9P
|
Docetaxel
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCE6JV4
|
Docetaxel
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Docetaxel + Arsenic trioxide
|
DCX834M
|
Docetaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
ER819762 + Arsenic trioxide
|
DC73CHT
|
ER819762
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
ER819762 + Arsenic trioxide
|
DC2YSAY
|
ER819762
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
ER819762 + Arsenic trioxide
|
DC3QD26
|
ER819762
|
Glioma (Cell Line: SF-539)
|
[4] |
|
ER819762 + Arsenic trioxide
|
DCAV52W
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
ER819762 + Arsenic trioxide
|
DCI21R2
|
ER819762
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
ER819762 + Arsenic trioxide
|
DCJZSR6
|
ER819762
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
ER819762 + Arsenic trioxide
|
DCNRJ4O
|
ER819762
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
ER819762 + Arsenic trioxide
|
DCXMEOW
|
ER819762
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DCWV6PO
|
ER819762
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DC0LEW5
|
ER819762
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DCCNGVN
|
ER819762
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DCN5MCH
|
ER819762
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DCVA7PJ
|
ER819762
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ER819762 + Arsenic trioxide
|
DCBC9SK
|
ER819762
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Estramustine + Arsenic trioxide
|
DCLKGTA
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Estramustine + Arsenic trioxide
|
DCR5YEM
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Estramustine + Arsenic trioxide
|
DCROPAZ
|
Estramustine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Estramustine + Arsenic trioxide
|
DC64NA8
|
Estramustine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Fludarabine + Arsenic trioxide
|
DCNC862
|
Fludarabine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Fludarabine + Arsenic trioxide
|
DCE8WIZ
|
Fludarabine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Fludarabine + Arsenic trioxide
|
DCRN2E2
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Fludarabine + Arsenic trioxide
|
DCIESIP
|
Fludarabine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Fludarabine + Arsenic trioxide
|
DCH60BS
|
Fludarabine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
FORMESTANE + Arsenic trioxide
|
DCQ1SQR
|
FORMESTANE
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC7P6WF
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC0RGBD
|
FORMESTANE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
FORMESTANE + Arsenic trioxide
|
DC3ITMB
|
FORMESTANE
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Fulvestrant + Arsenic trioxide
|
DCJ5A45
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Fulvestrant + Arsenic trioxide
|
DCJW5YB
|
Fulvestrant
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Fulvestrant + Arsenic trioxide
|
DCX8VF1
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Fulvestrant + Arsenic trioxide
|
DCHOM2A
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Gefitinib + Arsenic trioxide
|
DC4NJ7B
|
Gefitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Gefitinib + Arsenic trioxide
|
DCUBRGA
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Gefitinib + Arsenic trioxide
|
DC8QCHK
|
Gefitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Gefitinib + Arsenic trioxide
|
DC41P1H
|
Gefitinib
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Gefitinib + Arsenic trioxide
|
DCMTJ4S
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Hepzato + Arsenic trioxide
|
DCI9JCM
|
Hepzato
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Hepzato + Arsenic trioxide
|
DCSCR66
|
Hepzato
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Hepzato + Arsenic trioxide
|
DCWK6K9
|
Hepzato
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Idarubicin + Arsenic trioxide
|
DCDAF4M
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Idarubicin + Arsenic trioxide
|
DC2QYCU
|
Idarubicin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Ifosfamide + Arsenic trioxide
|
DCZ3VEU
|
Ifosfamide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Ixabepilone + Arsenic trioxide
|
DC8Y3AC
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Ixabepilone + Arsenic trioxide
|
DC1W1RD
|
Ixabepilone
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
JNK-IN-8 + Arsenic trioxide
|
DC7ANRV
|
JNK-IN-8
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
JNK-IN-8 + Arsenic trioxide
|
DCZSXH9
|
JNK-IN-8
|
Glioma (Cell Line: SF-539)
|
[4] |
|
JNK-IN-8 + Arsenic trioxide
|
DCQCRBM
|
JNK-IN-8
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
JNK-IN-8 + Arsenic trioxide
|
DCFGRTD
|
JNK-IN-8
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
JNK-IN-8 + Arsenic trioxide
|
DCNUQ6A
|
JNK-IN-8
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
JNK-IN-8 + Arsenic trioxide
|
DC5GLT1
|
JNK-IN-8
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
JNK-IN-8 + Arsenic trioxide
|
DCVDI1I
|
JNK-IN-8
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Lapatinib + Arsenic trioxide
|
DC6DUR0
|
Lapatinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Lapatinib + Arsenic trioxide
|
DCR8JFE
|
Lapatinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Lenalidomide + Arsenic trioxide
|
DCJBOQN
|
Lenalidomide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Lenalidomide + Arsenic trioxide
|
DCFS8BW
|
Lenalidomide
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Lenalidomide + Arsenic trioxide
|
DCKQNUQ
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Lenalidomide + Arsenic trioxide
|
DCPO80W
|
Lenalidomide
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Lenalidomide + Arsenic trioxide
|
DCZIEXG
|
Lenalidomide
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Lenalidomide + Arsenic trioxide
|
DCS70VN
|
Lenalidomide
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Lenalidomide + Arsenic trioxide
|
DCTSNP4
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Lenalidomide + Arsenic trioxide
|
DCYH18O
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Lenalidomide + Arsenic trioxide
|
DCBWSPB
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
LIAROZOLE + Arsenic trioxide
|
DCE7E1L
|
LIAROZOLE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
LIAROZOLE + Arsenic trioxide
|
DCHCHIZ
|
LIAROZOLE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
LIAROZOLE + Arsenic trioxide
|
DC5EBXZ
|
LIAROZOLE
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Mechlorethamine + Arsenic trioxide
|
DCOWU0S
|
Mechlorethamine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Mechlorethamine + Arsenic trioxide
|
DCEIULB
|
Mechlorethamine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Mechlorethamine + Arsenic trioxide
|
DCF4FRF
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Mechlorethamine + Arsenic trioxide
|
DCT8YA3
|
Mechlorethamine
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Mechlorethamine + Arsenic trioxide
|
DCE7VNY
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Mechlorethamine + Arsenic trioxide
|
DC9JANL
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Mechlorethamine + Arsenic trioxide
|
DCN4O90
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Mechlorethamine + Arsenic trioxide
|
DCYCN5H
|
Mechlorethamine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Mechlorethamine + Arsenic trioxide
|
DC3WWTN
|
Mechlorethamine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Mechlorethamine + Arsenic trioxide
|
DCEEJFW
|
Mechlorethamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Mepacrine + Arsenic trioxide
|
DCI8Q89
|
Mepacrine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Mepacrine + Arsenic trioxide
|
DCFL289
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Mepacrine + Arsenic trioxide
|
DC3LN1H
|
Mepacrine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Mepacrine + Arsenic trioxide
|
DCPP4SP
|
Mepacrine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Mepacrine + Arsenic trioxide
|
DC0TUXN
|
Mepacrine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Mercaptopurine + Arsenic trioxide
|
DCN60AQ
|
Mercaptopurine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Mercaptopurine + Arsenic trioxide
|
DCMMAC1
|
Mercaptopurine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Mercaptopurine + Arsenic trioxide
|
DCBMHXA
|
Mercaptopurine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Mercaptopurine + Arsenic trioxide
|
DC857Z3
|
Mercaptopurine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Methotrexate + Arsenic trioxide
|
DCV0GGD
|
Methotrexate
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Mitomycin + Arsenic trioxide
|
DCXMJXN
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Mitomycin + Arsenic trioxide
|
DCSBR41
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DCHNWI4
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DCU4W0J
|
Mitomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DCBQXHJ
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DCA71W4
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DC2FQY1
|
Mitomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Mitomycin + Arsenic trioxide
|
DCIQTN2
|
Mitomycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Nilotinib + Arsenic trioxide
|
DCINO6S
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
Nilotinib + Arsenic trioxide
|
DCF9O16
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Pentostatin + Arsenic trioxide
|
DCPZV47
|
Pentostatin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Pentostatin + Arsenic trioxide
|
DCPNI3N
|
Pentostatin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Picoplatin + Arsenic trioxide
|
DCWFV3R
|
Picoplatin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Picoplatin + Arsenic trioxide
|
DCECBAP
|
Picoplatin
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Picoplatin + Arsenic trioxide
|
DC08QGV
|
Picoplatin
|
Glioma (Cell Line: SF-295)
|
[4] |
|
Picoplatin + Arsenic trioxide
|
DCTBULJ
|
Picoplatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Picoplatin + Arsenic trioxide
|
DC25N5H
|
Picoplatin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Picoplatin + Arsenic trioxide
|
DCIHX1F
|
Picoplatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Picoplatin + Arsenic trioxide
|
DCYR6CU
|
Picoplatin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Picoplatin + Arsenic trioxide
|
DCG8NCE
|
Picoplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Picoplatin + Arsenic trioxide
|
DCB538R
|
Picoplatin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Picoplatin + Arsenic trioxide
|
DC9191G
|
Picoplatin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Plicamycin + Arsenic trioxide
|
DC4SB25
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC4JO3B
|
PMID28460551-Compound-2
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC2K2PC
|
PMID28460551-Compound-2
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC7A5HC
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DCTM1SU
|
PMID28460551-Compound-2
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[5] |
|
PMID28460551-Compound-2 + Arsenic trioxide
|
DC9X5OP
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
PMID28870136-Compound-43 + Arsenic trioxide
|
DCXGGCZ
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
PMID28870136-Compound-43 + Arsenic trioxide
|
DC5GN4I
|
PMID28870136-Compound-43
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCRAXZ1
|
Pralatrexate
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCZCG7S
|
Pralatrexate
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCFCS04
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCYMR2B
|
Pralatrexate
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DCBFCT5
|
Pralatrexate
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DC7ECE7
|
Pralatrexate
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Pralatrexate + Arsenic trioxide
|
DC6XVWF
|
Pralatrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DC8OS0G
|
Pralatrexate
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DC0K0H0
|
Pralatrexate
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCPL1BR
|
Pralatrexate
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCR9908
|
Pralatrexate
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Pralatrexate + Arsenic trioxide
|
DCF7QPZ
|
Pralatrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Raloxifene + Arsenic trioxide
|
DCI4C4X
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Raloxifene + Arsenic trioxide
|
DCWX5UO
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Raloxifene + Arsenic trioxide
|
DCBV35L
|
Raloxifene
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Romidepsin + Arsenic trioxide
|
DC30I5O
|
Romidepsin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[4] |
|
Romidepsin + Arsenic trioxide
|
DC2CN7Z
|
Romidepsin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Romidepsin + Arsenic trioxide
|
DCTG53M
|
Romidepsin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Romidepsin + Arsenic trioxide
|
DC9ZDL3
|
Romidepsin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Ruxolitinib + Arsenic trioxide
|
DCQO5OD
|
Ruxolitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Sirolimus + Arsenic trioxide
|
DC1EMRK
|
Sirolimus
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Sirolimus + Arsenic trioxide
|
DC5F1Z6
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Sirolimus + Arsenic trioxide
|
DC1MCVN
|
Sirolimus
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Sirolimus + Arsenic trioxide
|
DC3QU7Y
|
Sirolimus
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Sirolimus + Arsenic trioxide
|
DCLRLZT
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Sirolimus + Arsenic trioxide
|
DCDRB5E
|
Sirolimus
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCSRV4W
|
Sirolimus
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCSQTXM
|
Sirolimus
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCFTQC8
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCBDNQ8
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCC68GG
|
Sirolimus
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCE5AJS
|
Sirolimus
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Sirolimus + Arsenic trioxide
|
DCF8OCK
|
Sirolimus
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Sorafenib + Arsenic trioxide
|
DCL6MGI
|
Sorafenib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Sorafenib + Arsenic trioxide
|
DCQLZR0
|
Sorafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Sorafenib + Arsenic trioxide
|
DC910AU
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Sorafenib + Arsenic trioxide
|
DCYS81C
|
Sorafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
SY-1425 + Arsenic trioxide
|
DCUZ9FI
|
SY-1425
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
SY-1425 + Arsenic trioxide
|
DCOINMX
|
SY-1425
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
SY-1425 + Arsenic trioxide
|
DCGWJE7
|
SY-1425
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Taxol + Arsenic trioxide
|
DCUH2IK
|
Taxol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Taxol + Arsenic trioxide
|
DCQ09OO
|
Taxol
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Taxol + Arsenic trioxide
|
DCLNK5Y
|
Taxol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Taxol + Arsenic trioxide
|
DCLDH3Z
|
Taxol
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Taxol + Arsenic trioxide
|
DCC8CB0
|
Taxol
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Taxol + Arsenic trioxide
|
DCJMDWK
|
Taxol
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Taxol + Arsenic trioxide
|
DCP0W50
|
Taxol
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Taxol + Arsenic trioxide
|
DCEBIK2
|
Taxol
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Terameprocol + Arsenic trioxide
|
DCUPFE5
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Terameprocol + Arsenic trioxide
|
DCGYSTW
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Thioguanine + Arsenic trioxide
|
DC98DT6
|
Thioguanine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topetecan + Arsenic trioxide
|
DC40ZSH
|
Topetecan
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Topetecan + Arsenic trioxide
|
DC304H3
|
Topetecan
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Topetecan + Arsenic trioxide
|
DCVVTLV
|
Topetecan
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Topetecan + Arsenic trioxide
|
DCAHTFK
|
Topetecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Topetecan + Arsenic trioxide
|
DCQUZTG
|
Topetecan
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Topetecan + Arsenic trioxide
|
DCQSQ8J
|
Topetecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCCSSED
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[5] |
|
Topotecan + Arsenic trioxide
|
DCT6P7N
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DC4ZWNX
|
Topotecan
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCTLM1L
|
Topotecan
|
Astrocytoma (Cell Line: SNB-19)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCWPW4N
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DC4PRS5
|
Topotecan
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCGTF42
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCGAFHX
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DCILY7K
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DC54I6G
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DC36Y3O
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Topotecan + Arsenic trioxide
|
DC02J4O
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Trifluridine + Arsenic trioxide
|
DC7730D
|
Trifluridine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Trifluridine + Arsenic trioxide
|
DCU9BM4
|
Trifluridine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[5] |
|
Trifluridine + Arsenic trioxide
|
DCAUCJW
|
Trifluridine
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Trifluridine + Arsenic trioxide
|
DCLXNOC
|
Trifluridine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Trifluridine + Arsenic trioxide
|
DCUMLUM
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Trifluridine + Arsenic trioxide
|
DCI1Q3F
|
Trifluridine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Valrubicin + Arsenic trioxide
|
DC7UX2B
|
Valrubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Valrubicin + Arsenic trioxide
|
DCBJ7DW
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Valrubicin + Arsenic trioxide
|
DCVS9DD
|
Valrubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Valrubicin + Arsenic trioxide
|
DCC87YF
|
Valrubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Valrubicin + Arsenic trioxide
|
DC9538N
|
Valrubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[5] |
|
Valrubicin + Arsenic trioxide
|
DCZREZV
|
Valrubicin
|
Colon carcinoma (Cell Line: KM12)
|
[5] |
|
Valrubicin + Arsenic trioxide
|
DCGV3EZ
|
Valrubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Valrubicin + Arsenic trioxide
|
DCEYHC9
|
Valrubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Vandetanib + Arsenic trioxide
|
DC1IZT9
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vandetanib + Arsenic trioxide
|
DCW52RL
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DCSZDO8
|
Vemurafenib
|
Carcinoma (Cell Line: RXF 393)
|
[5] |
|
Vemurafenib + Arsenic trioxide
|
DCCZZSN
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Vemurafenib + Arsenic trioxide
|
DC5JA0F
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DCUSIHG
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DCXMVW3
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DC5RF4H
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vemurafenib + Arsenic trioxide
|
DC1PFT6
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
|
Vincristine + Arsenic trioxide
|
DCF2KPR
|
Vincristine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vincristine + Arsenic trioxide
|
DC12ASV
|
Vincristine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCI6HVH
|
Vincristine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCW1JNP
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCGJVZQ
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCWFCOF
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCT6DR5
|
Vincristine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DC9HTM1
|
Vincristine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vincristine + Arsenic trioxide
|
DCMATW5
|
Vincristine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[5] |
|
Vinflunine + Arsenic trioxide
|
DCCQXZG
|
Vinflunine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vinflunine + Arsenic trioxide
|
DCUUMKG
|
Vinflunine
|
Astrocytoma (Cell Line: U251)
|
[4] |
|
Vinflunine + Arsenic trioxide
|
DC9G9CN
|
Vinflunine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vinflunine + Arsenic trioxide
|
DC1933G
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[5] |
|
Vinflunine + Arsenic trioxide
|
DCSBIH1
|
Vinflunine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vinflunine + Arsenic trioxide
|
DC2BYQO
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Vinflunine + Arsenic trioxide
|
DCMOQD1
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vinflunine + Arsenic trioxide
|
DCUFWM1
|
Vinflunine
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vinflunine + Arsenic trioxide
|
DCBW25Z
|
Vinflunine
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCK1SLN
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DC295ES
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCMM3Z1
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCD4QD2
|
Vismodegib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCURCEA
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCOJ520
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DC8M0QQ
|
Vismodegib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vismodegib + Arsenic trioxide
|
DCCCW2M
|
Vismodegib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
